Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143

microRNA-143 acts as a suppressor of hemangioma growth by targeting Bcl-2

(2017) Chongqing Huang et al.   GENE

MiR-133b inhibits growth of human gastric cancer cells by silencing pyruvate kinase muscle-splicer polypyrimidine tract-binding protein 1

(2016) Taro Sugiyama et al.   CANCER SCIENCE

Feedback activation of neurofibromin terminates growth factor-induced Ras activation

(2016) Anne Hennig et al.   Cell Communication and Signaling

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer

(2016) Tanguy Y. Seiwert et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

(2016) Muhammad S. Beg et al.   INVESTIGATIONAL NEW DRUGS

MicroRNA-143 targets CD44 to inhibit breast cancer progression and stem cell-like properties

(2016) ZHUANGQING YANG et al.   Molecular Medicine Reports

MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer

(2015) Kohei Taniguchi et al.   CANCER LETTERS

Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole–imidazole polyamide conjugate

(2015) Kiriko Hiraoka et al.   Nature Communications

Organ-specific PTB1-associated microRNAs determine expression of pyruvate kinase isoforms

(2015) Kohei Taniguchi et al.   Scientific Reports

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange

(2014) Michael C. Burns et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance

(2013) Xianghui Zeng et al.   BIOMATERIALS

Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways

(2012) Shunsuke Noguchi et al.   CANCER LETTERS

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Forced Expression of miR-143 Represses ERK5/c-Myc and p68/p72 Signaling in Concert with miR-145 in Gut Tumors of ApcMin Mice

(2012) Yuji Takaoka et al.   PLoS One

MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells

(2011) Syunsuke Noguchi et al.   CANCER LETTERS

Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

(2011) Cecily P. Vaughn et al.   GENES CHROMOSOMES & CANCER

MicroRNAs in Development and Disease

(2011) Danish Sayed et al.   PHYSIOLOGICAL REVIEWS

MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo

(2010) S Vidic et al.   CANCER GENE THERAPY

Role of anti-oncomirs miR-143 and -145 in human colorectal tumors

(2010) Y Akao et al.   CANCER GENE THERAPY

NRAS Mutations Are Rare in Colorectal Cancer

(2010) Natsumi Irahara et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

MicroRNA-Based Therapeutics for Cancer

(2009) Vivien Wang et al.   BIODRUGS

Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells

(2009) Yukihiro Akao et al.   LEUKEMIA RESEARCH

Role of miR-143 targeting KRAS in colorectal tumorigenesis

(2009) X Chen et al.   ONCOGENE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE